MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from short-term
convertible notes
$281,438
Proceeds from short-term
promissory notes
$3,000
Net cash provided by
financing activities
$284,438
Net increase in cash
$85,112
Canceled cashflow
$199,326
Accretion of original
issuance costs
$119,739
Accrued payroll and
payroll taxes
$93,645
Accretion of debt discount
-$70,211
Stock based
compensation
$50,000
Accounts payable
$43,758
Other current assets
-$1,300
Other current
liabilities
$524
Net cash used in
operating activities
-$199,326
Canceled cashflow
$379,177
Net loss
-$578,503
Back
Back
Cash Flow
source: myfinsight.com
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)